Addendum
Nivolumab - Addendum to Commission A15-27
Report documents
-
Addendum
Nivolumab - Addendum to Commission A15-27
Press releases
Nivolumab in melanoma: data subsequently submitted improve assessment result
The extent of added benefit increased to "considerable" in women with BRAF V600 wt tumour, and to "major" in men
Additional information
Federal Joint Committee (G-BA)
2016-01-07 A G-BA decision was published.
Project details
- Project no.
- A15-50
- Commission
- Commission awarded on 25.11.2015 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair, Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Nivolumab – Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed